Each 10 mL of syrup contains Ambroxol Hydrochloride 30 mg, Terbutaline Sulphate IP 2.5 mg, and Guaiphenesin 100 mg.

Ventryl Syrup is a triple-action respiratory formulation containing Terbutaline Sulphate, Ambroxol Hydrochloride, and Guaiphenesin. It is designed to provide effective symptomatic relief from bronchospasm and productive cough by combining bronchodilator, mucolytic, and expectorant actions. The formulation helps relax bronchial smooth muscles, loosen thick mucus, and facilitate the clearance of respiratory secretions, improving breathing comfort and reducing chest congestion.

Ventryl Syrup is indicated for the symptomatic relief of bronchospasm associated with bronchial asthma and chronic bronchitis. It helps relieve productive cough, wheezing, chest congestion, and breathing difficulty by improving airway patency and promoting effective mucus clearance.

Terbutaline is a selective β₂-adrenergic receptor agonist that produces bronchodilation by relaxing bronchial smooth muscles. It also enhances mucociliary clearance, suppresses airway edema, and exhibits anti-allergic effects that improve respiratory function. Ambroxol Hydrochloride acts as a mucolytic and expectorant, reducing the viscosity of bronchial secretions and facilitating easier expectoration. Guaiphenesin is an expectorant that increases the volume and decreases the thickness of respiratory secretions, promoting productive coughing and effective mucus removal from the airways.

The recommended dosage is 10–20 mL three times daily for adults, 10 mL three times daily for children aged 6–12 years, and 5–10 mL three times daily for children under 6 years, or as directed by the physician.

Ventryl Syrup is contraindicated in patients with known hypersensitivity to Terbutaline Sulphate, Ambroxol Hydrochloride, Guaiphenesin, or any component of the formulation. It should not be used in patients with pre-existing ischemic heart disease, significant risk factors for ischemic heart disease, or active gastric ulceration.